Saturday 17 October 2026
Export IMCR’s income statement to Excel — free account
Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.
29.40
0.08
−0.27%
Follow IMCR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 6 |
+8 more TTM periods Free account |
| (4.47%) | (7.14%) | (9.58%) | (7.55%) | ||
| (1.64%) | (2.63%) | (3.42%) | (2.67%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(2.18%) | (3.55%) | (4.66%) | (3.39%) | |
Average Days of Receivables |
80.79 | 71.68 | 67.50 | 72.96 | |
Free Cash Flow per Share |
(0.81) | (0.61) | (0.30) | 0.06 | |
Free Cash Flow |
(41.15) | (30.74) | (15.05) | 2.99 | |
Capital Expenditures |
(6.19) | (5.82) | (4.34) | (5.00) | |
| Other line items | |||||
Cash ROIC |
(2.43%) | (1.88%) | (0.92%) | 0.18% | |
Accounts Receivable Turnover |
5.22 | 5.73 | 5.84 | 5.44 | |
Accounts Payable Turnover |
0.19 | 0.16 | 0.21 | 0.13 | |
Inventory Turnover |
0.72 | 0.62 | 0.83 | 0.53 | |
Average Days of Payables |
2,027.53 | 2,346.97 | 1,748.15 | 3,087.30 | |
Days of Inventory on Hand |
600.19 | 642.29 | 483.75 | 760.53 | |
Tax Rate |
5.62 | 1.31 | 0.86 | 0.04 | |
Research and Development Expense of Revenue |
66.03% | 67.71% | 68.71% | 67.68% | |
Selling, General and Administrative Expense of Revenue |
38.11% | 39.50% | 41.35% | 43.49% | |
Share Based Compensation of Revenue |
7.87% | 8.36% | 9.42% | 10.02% | |
Interest Coverage |
(1.85) | (2.83) | (3.73) | (2.79) | |
Operating CF/Net income |
1.93 | 0.90 | 0.30 | (0.27) | |
Depreciation/Fixed assets |
0.28 | 0.28 | 0.28 | 0.38 | |
Capex/Depreciation |
(1.72) | (1.73) | (1.33) | (1.39) | |
Revenue per Share |
8.45 | 8.13 | 7.95 | 7.53 | |
Operating CF per Share |
(0.69) | (0.49) | (0.21) | 0.16 | |
Capex per Share |
(0.12) | (0.11) | (0.09) | (0.10) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates